GI bleeding
Transcription
GI bleeding
GI bleeding GI bleeding Term: Hematemesis : bloody vomitus Melena: tarry stool passage Maroon : tarry- bloody stool passage Hematochezia: bloody stool passage 1 GI bleeding Bleeding > 5~10ml Æ OB (+) Bleeding > 50~100ml Æ tarry stool Bleeding above Treitz lig.Æ hematemesis Bleeding above ileocecal valve Æ tarry stool Bleeding below ileocecal valve Æ fresh bloody stool 1. R’t side colon Æ blood mixed inside the stool 2. L’t side colon Æ blood coated outside the stool 3.rectosigmoid Æ fresh bloody discharge Common cause of acute UGI bleeding Erosive, hemorrhagic gastropathy ( aspirin, other NSAIDs) (3~11%) Ulcer: Gastric or duodenal ulcer (35~62%) Mallory-Weiss tear (4~13%) Varices – portal hypertensive gastropathy(4~31%) Arteriovenous malformation Maligancy (1~4%) No source identified ( 7~25%) 2 Common cause of acute LGI bleeding 1. 2. 3. 4. 5. < 55 y/o Anorectal disease ( hemorrhoid, fissures) Colitis (IBD, infection) Diverticulosis Polys, cancer Angiodysplasia 1. 2. 3. 4. 5. > 55 y/o Anorectal disease (hemorrhoid, fissures) Diverticulosis Angiodysplasia Polys, cancer Enterocolitic (ischemic, infection, IBD, radiation) Evaluated blood loss Blood loss % (ml) BP HR S/S 0~500 0~10% No change No change None 500~1000 10~20% <120bpm Peripheral cool 1000~1750 20~35% Posture hypotension 90<SBP<120 >120bpm +oliguria >1750 >35% SBP<90 <60bpm + shock 3 Peptic ulcer Phase of GU, DU Active stage: A1: well-defined, deep ulceration; marked bleeding from the ulcer base marginal welling A2: stop bleeding Healing stage (H): H1,H2,H3 Scarred stage (S): S1( red scar), S2(white scar) Forrest Grade I 4 Forrest Grade IIA IIB Forrest Grade IIC III 5 Peptic ulcer Risk of recurrent bleeding SRH: stigmata of recent hemorrhage exposure vessels adherent clots arterial spurting or oozing Endoscopic therapy HSE (hypertonic saline and epinephrine), bipolar electrocoagulation, heat probe, hematoclip, APC Risk factors > 60 y/o age More than one comorbid illness Blood loss > 5 units Shock on admission Bright-red hematemesis with hypotension Coagulopathy Large ( > 2cm) ulcer Recurrent hemorrrhage ( within 72 hrs) Requirement for emergency surgery 6 GI bleeding – goals of management Hemodynamic stable Active bleeding stopped Recurrent bleeding prevented Hemodynamic stable Pulse pressure > 30 mmHg SBP > 110 mmHg DBP > 70 mmHg HR < 100 bpm Good skin turgor 7 UGI bleeding -- management Restoration of intravascular volume Hct: > 25% Hct: > 30% in cardiac or pulmonary dz Æ Vasopressors indicated ? Vol resuscitation end-point CVP=15 mmHg Wedge pressure = 10 to 12 mmHg Blood lactate < 4 mmol/ L Base deficit –3 to +3 mmol/L C.I. > 3L/min/m2 UGI bleeding -- management O2 consumption ( V O2) = Q * Hb * (SaO2-SvO2) Volume deficit = % loss * normal blood volume Males – 70 ml / kg or 3.2 L/ M2 Females – 60 ml / kg or 2.9 L/ M2 8 UGI bleeding -- management Correction of coagulopathy Initial infusion: FFP 2~4 u Protamine infusion ( 1mg antagonizes =100 u of heparin) Vit-K (10 mg,IM): warfarin, hepatobiliary disease PLT transfusion: > 50000/cumm Airway protection PUD-- treatment Antacids drug interaction – Tetracyclines, Quinolone, ketoconazole, Peptic ulcer ( with evidence) H2-blocker: Ranitidine (Zantac, Quicran) side effect: headache, lethargy, confusion, depression drug interaction: Cimetidine Æ β-blockers, Metformin, Phenytoin, Procainamide, Theophylline, TCA and Warfarin. 9 PUD -- treatment Peptic ulcer ( with evidence) PPIs: Omeprazole ( Losec) -- elder -- intractable bleeding -- combine with theophylline Raise intragastric pH to 6~7 Enhance clot stablity decreased further bleeding (but not mortality) UGI bleeding -- treatment Variceal hemorrhage 1. Stabilize hemodynamic ( crystal with colloid supply) 2. Airway patent 3. NG decompression of early detect of rebleeding 4. Octreotide: Somatostatine (Somatosan) 2Amp add N/S to 50ml Æ loading 2ml and maintain 2ml/ hr 10 UGI bleeding -- treatment Variceal hemorrhage 5. Endoscopic therapy with ligation 6. Sclerotherapy 7. Balloon tamponade Sengstaken-Blakemore tube 8. Avoid hepatic encephalopathy 9. Prophylaxis: reduce portal hypertensoion -- Inderal, nitrates 10. Surgery Recurrent bleeding prevented Eradication of H.P Æ rebleeding rate < 5% Avoid NSAIDs 11 acute UGI bleeding if no hemodynamic change and no dropping Hb: routine endoscopy ulcer hemodynamic change and dropping Hb: urgent endoscopy EV active bleeding or visible vessel adherent clot or flat ,pigmented spot Endoscopic therapy no Endoscopic therapy no Endoscopic therapy ICU for 1~2 day ward for 2 to 3 days ICU for 1 day ward for 1 to 2 days ward for 3 days clear base discharge ligation or sclerotherapy Mallory-Weiss tear active bleeding no active bleeding Endoscopic therapy no Endoscopic therapy ward for 1~2 days discharge 12